RxDoctor Payments Data

Kongmong Moua

Physician Assistant · Fresno, CANPI 1811009244

Payments from drug & device makers

$4,230in general payments, 2019–2025

Across 202 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$807
  • Amgen$563
  • AstraZeneca$334
  • Pfizer$308
  • Boehringer Ingelheim$294
  • Gilead$240
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,230 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide74$90,365
Synjardy XrEmpagliflozin/Metformin Hcl76$50,695
JardianceEmpagliflozin31$24,877
OzempicSemaglutide22$19,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,227
Nurtec OdtRimegepant Sulfate17$16,134
SynjardyEmpagliflozin/Metformin Hcl16$15,641
JanuviaSitagliptin Phosphate29$14,954
RybelsusSemaglutide13$14,372
MounjaroTirzepatide15$13,668
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$13,236
Breo ElliptaFluticasone/Vilanterol26$13,170
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$12,197
Janumet XrSitagliptin Phos/Metformin Hcl21$11,451
Fiasp FlextouchInsulin Aspart (Niacinamide)15$8,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$807$104,03289 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy$294$91,213123 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$92$46,54370 claims
Novo NordiskOzempic, Rybelsus$147$33,70235 claims
MerckJanuvia, Janumet Xr$68$26,40550 claims
PfizerNurtec Odt$308$16,13417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →